Long-term outcome after LACE (lomustine, ara-C, cyclophosphamide, etoposide) conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma

被引：0
|
作者：
Perz, JB [1 ]
Giles, C [1 ]
Szydlo, RM [1 ]
Wagner, S [1 ]
Sanz, J [1 ]
Chaidos, A [1 ]
Apperley, JF [1 ]
MacDonald, D [1 ]
Kanfer, E [1 ]
机构：
[1] Hammersmith Hosp, London, England
来源：
BONE MARROW TRANSPLANTATION | 2006年 / 37卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S240 / S240
页数：1
相关论文
共 50 条
  • [1] Long-term outcome after LACE (Lomustine, Ara-C, Cyclophosphamide, Etoposide) conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: A single centre experience.
    Perz, JB
    Giles, CM
    MacDonald, D
    Apperley, JF
    Kanfer, EJ
    [J]. BLOOD, 2005, 106 (11) : 464B - 464B
  • [2] Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma
    Sirohi, B.
    Cunningham, D.
    Powles, R.
    Murphy, F.
    Arkenau, T.
    Norman, A.
    Oates, J.
    Wotherspoon, A.
    Horwich, A.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (07) : 1312 - 1319
  • [3] LACE (lomustine, ara-C, cyclophosphamide and etoposide): An effective conditioning regimen for autologous and allogeneic transplantation with minimal toxicity.
    Orchard, K
    Giles, C
    Apperley, J
    Goldman, JM
    Kanfer, EJ
    Samson, D
    [J]. BLOOD, 1997, 90 (10) : 1855 - 1855
  • [4] TECAM (THIOTEPA, ETOPOSIDE, CYCLOPHOSPHAMIDE, ARA-C AND MELPHALAN) AS CONDITONING REGIMEN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN AND HODGKIN LYMPHOMA
    Patir, P.
    Duran, M.
    Koseoglu, F.
    Uysal, A.
    Sahin, F.
    Tobu, M.
    Saydam, G.
    Vural, F.
    [J]. LEUKEMIA RESEARCH, 2016, 49 : S37 - S38
  • [5] Lace(lomustine, ARA-C, cyclophosphamide and etoposide): An effective conditioning regimen for autologous and allogeneic transplantation with minimal regimen-related toxicity
    Orchard, K
    Lyttelton, MP
    Abrahamson, G
    Stem, S
    Abboudi, Z
    McGuigan, D
    Giles, C
    Kanfer, EJ
    Samson, D
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 969 - 969
  • [6] Long-term outcome of survivors of autologous hematopoietic-cell transplantation for refractory and relapsed Hodgkin lymphoma
    Goodman, K. A.
    Riedel, E.
    Serrano, V.
    Gonzales, A. M.
    Gulati, S.
    Moskowitz, C.
    Yahalom, J.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 48 - 49
  • [7] Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma
    Majhail, Navneet S.
    Weisdorf, Daniel J.
    Defor, Todd E.
    Miller, Jeffrey S.
    McGlave, Philip R.
    Slungaard, Arne
    Arora, Mukta
    Ramsay, Norma K. C.
    Orchard, Paul J.
    MacMillan, Margaret L.
    Burns, Linda J.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (10) : 1065 - 1072
  • [8] CARMUSTINE, ARA-C, CYCLOPHOSPHAMIDE AND ETOPOSIDE WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN RELAPSED OR REFRACTORY LYMPHOMA - A DOSE-FINDING STUDY
    SNYDER, MJ
    JOHNSON, DB
    DALY, MB
    GIGUERE, JK
    HARMAN, GH
    HARDEN, EA
    JOHNSON, RA
    LEFF, RS
    MERCIER, RJ
    MESSERSCHMIDT, GL
    RUBINSAK, JR
    ESSELL, JH
    HALVORSON, RD
    THOMPSON, JM
    [J]. BONE MARROW TRANSPLANTATION, 1994, 14 (04) : 595 - 600
  • [9] TECAM (thiotepa, etoposide, cyclophosphamide, Ara-c and melphalan) as conditoning regimen for autologous stem cell transplantation in patients with lymphoma
    Patir, P.
    Soyer, N.
    Sahin, F.
    Saydam, G.
    Tobu, M.
    Tombuloglu, M.
    Vural, F.
    [J]. BONE MARROW TRANSPLANTATION, 2017, 52 : S336 - S337
  • [10] Long term follow-up after autologous stem cell transplantation in refractory or relapsed Hodgkin lymphoma
    Stamatoullas, A.
    Lanic, H.
    Contentin, N.
    Nunes, K.
    Picquenot, J. M.
    Bastard, C.
    Tilly, H.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 78 - 78
12345